Microdosing GLP-1 GIP B12 for longevity A separate and distinct use case has emerged for tirzepatide and GLP-1 class agents: microdosing for metabolic health, anti-inflammatory effects, and longevity, independent of weight loss goals
Retatrutide, an investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly, demonstrated unprecedented weight loss in Phase 2 trials but has not yet completed Phase 3 development
doi: 10.1016/0091-3057(89)90477-2 8 BeyerC
Retatrutide powder should be stored at 20C in sealed amber vials, away from light and moisture, exclusively within regulated clinical trial or research pharmacy settings, as it is not a licensed medicine in the UK
FP Work touches on HR strategy, labour economics, office culture, technology and more